SCHEMBL6447779

SCHEMBL6447779

CCOC(=O)c1ccc(OC)c(OCCCN2CCOCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
CYP2D6 P10635 2/20 0.59
CYP2C9 P11712 1/20 0.59
KDM4E B2RXH2 4/20 0.57
GAA P10253 1/20 0.57
PKM P14618 1/20 0.57
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SLC29A1 Q99808 1/20 0.52
TSHR P16473 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KCNH2 Q12809 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3531517 0.96 SMN1; SMN2 (0.63) SMN1; SMN2CYP2D6CYP2C9KDM4EGAA
SCHEMBL3470303 0.90 CYP2D6 (0.65) SMN1; SMN2CYP2D6CYP2C9KDM4EGAA
SCHEMBL13503073 0.87 EPHX2 (0.58) SMN1; SMN2KDM4EGAAPKMMAPK1
SCHEMBL3930162 0.84 SMN1; SMN2 (0.65) SMN1; SMN2CYP2D6CYP2C9KDM4EGAA
SCHEMBL13380211 0.82 CYP2D6 (0.64) SMN1; SMN2CYP2D6CYP2C9KDM4ETDP1
SCHEMBL5494919 0.82 KDM4E (0.66) SMN1; SMN2CYP2D6CYP2C9KDM4ETDP1
SCHEMBL5214308 0.82 HRH3 (0.72) SMN1; SMN2KDM4EGAAALDH1A1HPGD
SCHEMBL4495057 0.81 SMN1; SMN2 (0.58) SMN1; SMN2KDM4EGAAPKMALDH1A1
SCHEMBL5562205 0.81 SMN1; SMN2 (0.55) SMN1; SMN2KDM4EGAAPKMALDH1A1
SCHEMBL27793487 0.81 ALDH1A1 (0.57) SMN1; SMN2CYP2D6CYP2C9KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1263503-B1 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS WYETH CORP (US) 2005-11-02 EP disclosed
EP-1117659-B1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS WYETH CORP (US) 2003-12-03 EP disclosed
EP-0973746-B1 SUBSTITUTED 3-CYANO QUINOLINES WYETH CORP (US) 2003-09-24 EP disclosed
EP-1263503-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2002-12-11 EP disclosed
WO-2001068186-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2001-09-20 WO disclosed
US-6288082-B1 COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE AMERICAN CYANAMID COMPANY 2001-09-11 US disclosed
EP-1117659-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS American Cyanamid Company (US) 2001-07-25 EP disclosed
WO-2000018761-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-04-06 WO disclosed
US-6002008-A Substituted 3-cyano quinolines AMERICAN CYANAMID COMPANY 1999-12-14 US disclosed